Chester County News and Community Website
MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) recently announced that it has enrolled the first 143 patients in its pivotal Phase 3 REVERSE-IT trial for its lead product candidate …
PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial Read More
MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) this week announced that the Investigational New Drug (IND) application for bentracimab submitted to the Center for Drug Evaluation (CDE) of the …
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals Announce Approval of IND Application in China for Bentracimab Read More MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, recently announced that it has entered …
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A Read More MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, recently highlighted a presentation of healthcare …
PhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Read More MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today highlighted real-world evidence presented over …
PhaseBio Highlights Real-World Bleeding, Surgery Data at American College of Cardiology’s Annual Scientific Session Read More MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, has provided an update on corporate …
PhaseBio Reports First-Quarter 2021 Financial Results Read More MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) announced that Chief Financial Officer John Sharp will provide a company overview at the 20th Annual Needham Virtual Healthcare Conference on April …
PhaseBio to Present at 20th Annual Needham Virtual Healthcare Conference Read More
MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, this week announced the closing of …
Chester County-based Pharmaceutical Grossed $64.4 Million from Public Offering Read More MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, this week reported financial results for …
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results Read More MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global …
PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement Read More